The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Chemotherapy-Induced Nausea and Vomiting (CINV)-Global Market Insights and Sales Trends 2024
Synopsis
Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the devastating side effects for patients undergoing cancer treatment. It is caused when various types of poisonous substances such as chemotherapeutic agents enter in the human body and alert the digestive system during chemotherapy. Besides chemotherapy, there are various types of factors that puts a patient high risk for CINV including female sex, history of alcohol use, CINV & motion sickness and anxiety or depression.
The global Chemotherapy-Induced Nausea and Vomiting (CINV) market size is expected to reach US$ 3044.6 million by 2029, growing at a CAGR of 2.5% from 2023 to 2029. The market is mainly driven by the significant applications of Chemotherapy-Induced Nausea and Vomiting (CINV) in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers and Diagnostic Centers,, are propelling Chemotherapy-Induced Nausea and Vomiting (CINV) market. CINV, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the PONV segment is estimated at % CAGR for the next seven-year period.
The global CINV & PONV market is expected to grow with increasing cancer incidence, growing female population, increasing pharmaceutical R&D spending, growing healthcare expenditure and accelerating economic growth. Key trends and developments of this market includes progressing drugs under pipeline, high demand for combination therapy and increasing preference for pressure point therapy. However, there are some factors which can hinder growth of the market including entry of generics, stringent regulations and treatment cost.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Chemotherapy-Induced Nausea and Vomiting (CINV), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Chemotherapy-Induced Nausea and Vomiting (CINV) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Chemotherapy-Induced Nausea and Vomiting (CINV) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Chemotherapy-Induced Nausea and Vomiting (CINV) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Chemotherapy-Induced Nausea and Vomiting (CINV) covered in this report include Merck, Eisai, ProStrakan, Helsinn Holding, Mundipharma, Qilu Pharma, Teva, Novartis and Heron Therapeutics, etc.
The global Chemotherapy-Induced Nausea and Vomiting (CINV) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Eisai
ProStrakan
Helsinn Holding
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
Global Chemotherapy-Induced Nausea and Vomiting (CINV) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Chemotherapy-Induced Nausea and Vomiting (CINV) market, Segment by Type:
CINV
PONV
Global Chemotherapy-Induced Nausea and Vomiting (CINV) market, by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Chemotherapy-Induced Nausea and Vomiting (CINV) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the devastating side effects for patients undergoing cancer treatment. It is caused when various types of poisonous substances such as chemotherapeutic agents enter in the human body and alert the digestive system during chemotherapy. Besides chemotherapy, there are various types of factors that puts a patient high risk for CINV including female sex, history of alcohol use, CINV & motion sickness and anxiety or depression.
The global Chemotherapy-Induced Nausea and Vomiting (CINV) market size is expected to reach US$ 3044.6 million by 2029, growing at a CAGR of 2.5% from 2023 to 2029. The market is mainly driven by the significant applications of Chemotherapy-Induced Nausea and Vomiting (CINV) in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers and Diagnostic Centers,, are propelling Chemotherapy-Induced Nausea and Vomiting (CINV) market. CINV, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the PONV segment is estimated at % CAGR for the next seven-year period.
The global CINV & PONV market is expected to grow with increasing cancer incidence, growing female population, increasing pharmaceutical R&D spending, growing healthcare expenditure and accelerating economic growth. Key trends and developments of this market includes progressing drugs under pipeline, high demand for combination therapy and increasing preference for pressure point therapy. However, there are some factors which can hinder growth of the market including entry of generics, stringent regulations and treatment cost.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Chemotherapy-Induced Nausea and Vomiting (CINV), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Chemotherapy-Induced Nausea and Vomiting (CINV) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Chemotherapy-Induced Nausea and Vomiting (CINV) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Chemotherapy-Induced Nausea and Vomiting (CINV) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Chemotherapy-Induced Nausea and Vomiting (CINV) covered in this report include Merck, Eisai, ProStrakan, Helsinn Holding, Mundipharma, Qilu Pharma, Teva, Novartis and Heron Therapeutics, etc.
The global Chemotherapy-Induced Nausea and Vomiting (CINV) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Eisai
ProStrakan
Helsinn Holding
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
Global Chemotherapy-Induced Nausea and Vomiting (CINV) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Chemotherapy-Induced Nausea and Vomiting (CINV) market, Segment by Type:
CINV
PONV
Global Chemotherapy-Induced Nausea and Vomiting (CINV) market, by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Chemotherapy-Induced Nausea and Vomiting (CINV) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Chemotherapy-Induced Nausea and Vomiting (CINV)
1.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview
1.1.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Product Scope
1.1.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Status and Outlook
1.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region (2018-2029)
1.4 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Historic Market Size by Region (2018-2023)
1.5 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2018-2029)
1.6.1 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2018-2029)
1.6.2 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2018-2029)
1.6.3 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2018-2029)
1.6.4 Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2018-2029)
1.6.5 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2018-2029)
2 Chemotherapy-Induced Nausea and Vomiting (CINV) Market by Type
2.1 Introduction
2.1.1 CINV
2.1.2 PONV
2.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Historic Market Size by Type (2018-2023)
2.2.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Breakdown by Type (2018-2029)
3 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Ambulatory Surgical Centers
3.1.3 Diagnostic Centers
3.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Historic Market Size by Application (2018-2023)
3.2.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Breakdown by Application (2018-2029)
4 Chemotherapy-Induced Nausea and Vomiting (CINV) Competition Analysis by Players
4.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) as of 2022)
4.3 Date of Key Players Enter into Chemotherapy-Induced Nausea and Vomiting (CINV) Market
4.4 Global Top Players Chemotherapy-Induced Nausea and Vomiting (CINV) Headquarters and Area Served
4.5 Key Players Chemotherapy-Induced Nausea and Vomiting (CINV) Product Solution and Service
4.6 Competitive Status
4.6.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Merck
5.1.1 Merck Profile
5.1.2 Merck Main Business
5.1.3 Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Products, Services and Solutions
5.1.4 Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (US$ Million) & (2018-2023)
5.1.5 Merck Recent Developments
5.2 Eisai
5.2.1 Eisai Profile
5.2.2 Eisai Main Business
5.2.3 Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Products, Services and Solutions
5.2.4 Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (US$ Million) & (2018-2023)
5.2.5 Eisai Recent Developments
5.3 ProStrakan
5.3.1 ProStrakan Profile
5.3.2 ProStrakan Main Business
5.3.3 ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Products, Services and Solutions
5.3.4 ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (US$ Million) & (2018-2023)
5.3.5 Helsinn Holding Recent Developments
5.4 Helsinn Holding
5.4.1 Helsinn Holding Profile
5.4.2 Helsinn Holding Main Business
5.4.3 Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Products, Services and Solutions
5.4.4 Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (US$ Million) & (2018-2023)
5.4.5 Helsinn Holding Recent Developments
5.5 Mundipharma
5.5.1 Mundipharma Profile
5.5.2 Mundipharma Main Business
5.5.3 Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Products, Services and Solutions
5.5.4 Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (US$ Million) & (2018-2023)
5.5.5 Mundipharma Recent Developments
5.6 Qilu Pharma
5.6.1 Qilu Pharma Profile
5.6.2 Qilu Pharma Main Business
5.6.3 Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Products, Services and Solutions
5.6.4 Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (US$ Million) & (2018-2023)
5.6.5 Qilu Pharma Recent Developments
5.7 Teva
5.7.1 Teva Profile
5.7.2 Teva Main Business
5.7.3 Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Products, Services and Solutions
5.7.4 Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (US$ Million) & (2018-2023)
5.7.5 Teva Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Products, Services and Solutions
5.8.4 Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (US$ Million) & (2018-2023)
5.8.5 Novartis Recent Developments
5.9 Heron Therapeutics
5.9.1 Heron Therapeutics Profile
5.9.2 Heron Therapeutics Main Business
5.9.3 Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Products, Services and Solutions
5.9.4 Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (US$ Million) & (2018-2023)
5.9.5 Heron Therapeutics Recent Developments
5.10 Roche
5.10.1 Roche Profile
5.10.2 Roche Main Business
5.10.3 Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Products, Services and Solutions
5.10.4 Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (US$ Million) & (2018-2023)
5.10.5 Roche Recent Developments
5.11 Mylan
5.11.1 Mylan Profile
5.11.2 Mylan Main Business
5.11.3 Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Products, Services and Solutions
5.11.4 Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (US$ Million) & (2018-2023)
5.11.5 Mylan Recent Developments
5.12 Tesaro
5.12.1 Tesaro Profile
5.12.2 Tesaro Main Business
5.12.3 Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Products, Services and Solutions
5.12.4 Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue (US$ Million) & (2018-2023)
5.12.5 Tesaro Recent Developments
6 North America
6.1 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Dynamics
11.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Industry Trends
11.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Drivers
11.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Challenges
11.4 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
